Meeting Coverage
ASCO
American Society of Clinical Oncology
Study suggests it may even be detrimental in some groups of patients on active surveillance
Latest ASCO Meeting Coverage
Dose-limiting toxicity has been linked with worse outcomes specifically in this population
Two trials show positive outcomes
A third as many clinical events versus adjuvant therapy, 6 weeks of treatment for many patients
Adjuvant chemo de-escalation based on ctDNA had no effect on recurrence-free survival
Three new trials address CRC liver metastases
Current option for rare tumor requires a REMS to monitor for drug-induced liver injury
Clear cell histology "is what yields the super response we see in these trials," expert suggests
Anticholinergic oxybutynin for patients taking ADT also improved quality of life in the process
Median OS was 55.9 months in the durvalumab group compared with 33.4 months in the placebo group
Improvement also observed in complete remission rates with FLOT over CROSS regimen
PFS was not significantly different for those who skipped lymphadenectomy
Benefit with BV plus lenalidomide-rituximab seen in those who relapsed after CAR-T or transplant
Trastuzumab deruxtecan extended its superiority versus chemotherapy into HER2-ultralow
Frontline treatment with mitazalimab plus mFOLFIRINOX achieved responses in 40% of patients